Model without adjustment for practice characteristics | Model with adjustment forpractice characteristics | ||||||
---|---|---|---|---|---|---|---|
Co-efficient | 95% CI | Co-efficient | 95% CI | ||||
Lower | Upper | Lower | Upper | ||||
2015–2016 QP | -0.172 | -0.176 | -0.168 | -0.166 | -0.170 | -0.162 | |
Months since QP | 0.014 | 0.013 | 0.014 | 0.014 | 0.013 | 0.014 | |
Season | Winter | Ref | Ref | Ref | Ref | Ref | Ref |
Spring | -0.040 | -0.043 | -0.038 | -0.044 | -0.046 | -0.041 | |
Summer | -0.153 | -0.156 | -0.150 | -0.139 | -0.142 | -0.136 | |
Autumn | -0.132 | -0.135 | -0.129 | -0.119 | -0.121 | -0.116 | |
Comorbidities | Respiratory disease | – | – | – | 0.021 | 0.018 | 0.024 |
Diabetes prevalence | – | – | – | 0.028 | 0.026 | 0.030 | |
Benzodiazepine anxiolytics prescription | – | – | – | 0.123 | 0.118 | 0.127 | |
Benzodiazepine hypnotics prescription | – | – | – | 0.160 | 0.157 | 0.164 | |
GPHC per 10 000 patients(spline terms) | GPHC1 (<4.91) | – | – | – | 0.013 | 0.011 | 0.015 |
GPHC2 (≥4.91 to ≤9.80) | – | – | – | -0.008 | -0.010 | -0.006 | |
GPHC3 (≥9.81 to ≤14.72) | – | – | – | 0.07 | 0.002 | 0.011 | |
GPHC4 (>14.72) | – | – | – | -0.006 | -0.021 | 0.008 |
Effects of GPHC are per one increase in GP number per 10 000 patients within each spline term. GPHC = GP headcount. QP = Quality Premium.